| 41.57 Delayed Data As of 4:00pm ET |  -0.26 / -0.62%Today’s Change | 40.19 Today|||52-Week Range 45.62 | -4.24% Year-to-Date |
| Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs 11:56am / Zacks.com - Paid Partner Content | Aimmune Down on Negative ICER Review on Allergy Candidate Jul 12 / Zacks.com - Paid Partner Content |
| Merck's Antibiotic Recarbrio Gets FDA Nod for Infections 11:06am / Zacks.com - Paid Partner Content | Are Investors Undervaluing Sanofi (SNY) Right Now? Jul 12 / Zacks.com - Paid Partner Content |
| Biechele Royce Advisors Buys Schlumberger, Intel Corp, CVS Health Corp, Sells Qualcom... Jul 16 / GuruFocus News - Paid Partner Content | Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY Jul 12 / Zacks.com - Paid Partner Content |
| AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes Jul 15 / Zacks.com - Paid Partner Content | FDA approves Dupixent?? (dupilumab) for chronic rhinosinusitis with nasal polyposis Jun 26 / PR NewswirePRN - Paid Partner Content |
| First Command Advisory Services, Inc. Buys iShares Core S&P Small-Cap, iShares Core S... Jul 15 / GuruFocus News - Paid Partner Content |
| Previous close | 41.83 |
| Today’s open | 41.85 |
| Day’s range | 41.54 - 41.93 |
| Volume | 714,949 |
| Average volume (3 months) | 1,343,604 |
| Market cap | $103.0B |
| Earnings growth (last year) | +19.94% |
| Earnings growth (this year) | +3.87% |
| Earnings growth (next 5 years) | +5.50% |
| Revenue growth (last year) | +2.83% |
| P/E ratio | 21.5 |
| Price/Sales | 2.68 |
| Price/Book | 1.53 |
| Today’s change | Today’s % change | |
|---|---|---|
| AZNAstraZeneca | +0.14 | +0.35% |
| LLYEli Lilly and Co | -1.73 | -1.59% |
| GSKGlaxoSmithKline | -0.04 | -0.10% |
| ABBVAbbVie | -0.84 | -1.21% |
| Next reporting date | July 29, 2019 |
| EPS forecast (this quarter) | $0.68 |
| Annual revenue (last year) | $40.7B |
| Annual profit (last year) | $5.1B |
| Net profit margin | 12.53% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Director Olivier Brandicourt |
Chief Financial Officer & Executive Vice President Jean-Baptiste Chasseloup de Chatillon |
Corporate headquarters Paris, Ile-de-france |
